MDS experts tell of the clinical factors they consider when selecting from the available agent options. An MDS expert panel discusses findings from the trial's comparison of luspatercept with ESAs in this setting. Mairéad Ní Chonghaile, RGN, BNS, MSc, speaks on the need for training and support networks in this area of care. Dr. Chedid brings an update highlighting the most noteworthy recent findings from MDS clinical trials. Kristen Howell, PhD, MPH, has investigated how transfer gaps in SCD care affect patients as they transition to adult care. Dr. Restrepo discusses coagulation and issues in coagulopathy risk screening in patients who have venous malformations. Konstanze Döhner, MD, met to discuss the background and ongoing progress of the EHA Lighting the Flame program. Dr. Vadivelan shared her study on pituitary and pancreatic iron deposition in patients with SCD at the 2024 ASPHO Conference. Dr. Ansong-Ansongton shared what National Minority Health Month and Celebrate Diversity Month mean to him at ASPHO 2024. Dr. Ansong-Ansongton described data on the impact of abnormal mitochondrial retention and cold in red blood cells in SCD. Dr. Mamauag details her study on the need for factor VIII infusions in patients with tolerized hemophilia A on emicizumab. Dr. Sharathkumar shared data from her 2024 ASPHO presentation on romiplostim in children with severe aplastic anemia and MDS. The study evaluated transplant outcomes in pediatric patients with SCD who had a history of red blood cell alloimmunization. Dr. Griffin shares data from their real-world study on pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria. Dr. Grunwald of the Atrium Health Levine Cancer Institute, discusses caring for patients with PV on rare disease day. Dr. Pakbaz describes some of the difficulties faced by patients with SCD as they switch from pediatric to adult programs. Drs. Grant, Sutin, and Lin discuss their pilot study investigating cerebral hemodynamics in infants with sickle cell disease. Dr. Pakbaz and Dr. Strouse discuss their experiences practicing classical hematology and where the speciality is heading. Dr. Pakbaz, from the University of California Irvine, shared data on the value of a dedicated classical hematology clinic. Dr. Pakbaz describes the significant need for specialists dedicated to adult patients with noncancer blood disorders.